Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront

June 29, 2026 07:15 AM EDTUpdated 11:21 AM DealsPharma Ipsen to buy blood can­cer com­pa­ny Kar­tos Ther­a­peu­tics for $450M up­front Ayisha Sharma News Reporter Ipsen is ear­mark­ing up to $1.75 bil­lion to take Kar­tos Ther­a­peu­tics and its MDM2 pro­tein-tar­get­ing drug can­di­date that it in-li­censed from Am­gen back in 2016. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER